Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATHE Alterity Therapeutics	$3.93 +0.3%	$4.16	$1.00 ▼ $5.87	$34.86M	0.8	144,516 shs	66,743 shs
BRNS Barinthus Biotherapeutics	$0.93 +0.8%	$0.91	$0.64 ▼ $1.58	$37.52M	-0.78	35,495 shs	2,016 shs
FBLG FibroBiologics	$0.62 -13.2%	$0.90	$0.62 ▼ $5.62	$23.65M	-0.79	297,562 shs	3.35 million shs
IBIO iBio	$0.76 +6.3%	$0.85	$0.64 ▼ $6.89	$12.47M	0.96	837,436 shs	2.02 million shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATHE Alterity Therapeutics	0.00%	-7.09%	-11.88%	+15.90%	+117.13%
BRNS Barinthus Biotherapeutics	0.00%	+10.57%	-12.26%	-4.39%	-33.57%
FBLG FibroBiologics	0.00%	-11.14%	-13.56%	-31.32%	-87.61%
IBIO iBio	0.00%	-2.08%	-1.63%	-81.22%	-64.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ATHE Alterity Therapeutics	2.6638 of 5 stars	3.3	5.0	2.2	1.7	0.0
BRNS Barinthus Biotherapeutics	3.3917 of 5 stars	3.5	5.0	3.3	0.0	1.3
FBLG FibroBiologics	2.9437 of 5 stars	3.6	2.0	2.2	3.3	0.6
IBIO iBio	1.6184 of 5 stars	3.5	0.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATHE Alterity Therapeutics	2.50	Moderate Buy	$12.00	205.34% Upside
BRNS Barinthus Biotherapeutics	3.00	Buy	$6.25	572.04% Upside
FBLG FibroBiologics	3.20	Buy	$13.00	2,003.22% Upside
IBIO iBio	3.00	Buy	$4.30	469.54% Upside

Current Analyst Ratings Breakdown

Latest IBIO, BRNS, FBLG, and ATHE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/25/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
6/17/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00
5/15/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
5/5/2025	IBIO iBio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
4/9/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/1/2025	FBLG FibroBiologics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	$1.04 per share	N/A
BRNS Barinthus Biotherapeutics	$14.97M	2.51	N/A	N/A	$3.23 per share	0.29
FBLG FibroBiologics	N/A	N/A	N/A	N/A	$0.08 per share	N/A
IBIO iBio	$375K	33.26	N/A	N/A	$1.41 per share	0.54

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATHE Alterity Therapeutics	-$12.54M	N/A	0.00	∞	N/A	N/A	N/A	N/A	8/4/2025 (Estimated)
BRNS Barinthus Biotherapeutics	-$61.07M	-$1.64	N/A	N/A	N/A	N/A	-46.43%	-38.50%	8/6/2025 (Estimated)
FBLG FibroBiologics	-$11.16M	-$0.21	N/A	N/A	N/A	N/A	-1,022.04%	-117.56%	8/6/2025 (Estimated)
IBIO iBio	-$24.91M	N/A	0.00	N/A	N/A	N/A	-73.15%	-45.51%	N/A

Latest IBIO, BRNS, FBLG, and ATHE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	FBLG FibroBiologics	-$0.10	-$0.14	-$0.04	-$0.14	N/A	N/A
5/7/2025	Q1 2025	BRNS Barinthus Biotherapeutics	-$0.34	-$0.49	-$0.15	-$0.49	N/A	N/A
3/31/2025	Q4 2024	FBLG FibroBiologics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
FBLG FibroBiologics	N/A	N/A	N/A	N/A	N/A
IBIO iBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATHE Alterity Therapeutics	N/A	3.84	N/A
BRNS Barinthus Biotherapeutics	N/A	9.18	9.18
FBLG FibroBiologics	N/A	1.14	1.14
IBIO iBio	0.05	1.76	1.76

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATHE Alterity Therapeutics	2.14%
BRNS Barinthus Biotherapeutics	25.20%
FBLG FibroBiologics	N/A
IBIO iBio	7.90%

Insider Ownership

Company	Insider Ownership
ATHE Alterity Therapeutics	38.80%
BRNS Barinthus Biotherapeutics	8.00%
FBLG FibroBiologics	20.80%
IBIO iBio	0.58%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATHE Alterity Therapeutics	10	8.87 million	5.43 million	Not Optionable
BRNS Barinthus Biotherapeutics	107	40.34 million	37.11 million	N/A
FBLG FibroBiologics	10	38.26 million	30.30 million	N/A
IBIO iBio	100	16.52 million	9.82 million	N/A

IBIO, BRNS, FBLG, and ATHE Headlines

Recent News About These Companies

Chardan Capital Reiterates Buy Rating for iBio (NYSE:IBIO)

June 27 at 2:11 AM | americanbankingnews.com

iBio Announces Conference Call to Review Myostatin and Activin E Antibody Data and Reveal Third Target in AstralBio Collaboration on June 24 | Nasdaq

June 24, 2025 | nasdaq.com

iBio Advances Obesity Care with Antibody Therapies

June 24, 2025 | tipranks.com

iBio and AstralBio Unveil Obesity Program with Novel Amylin Agonist Antibody Demonstrating Promising In Vivo Results

June 24, 2025 | globenewswire.com

iBio Presents Next-Generation Obesity and Cardiometabolic Pipeline Candidates on June 24 Conference Call

June 23, 2025 | globenewswire.com

iBio Extends Promissory Note Maturity to 2026

June 18, 2025 | tipranks.com

Ibio nominates IBIO-610 as obesity development candidate

June 18, 2025 | bioworld.comB

iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment

June 16, 2025 | globenewswire.com

Minister hails ‘exciting’ degree where students spend two years working in industry

May 29, 2025 | irishtimes.com

iBio’s First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025 | finance.yahoo.com

iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model

May 5, 2025 | globenewswire.com

iBio, Inc. Reports Strong Q3 2025 Progress

May 4, 2025 | tipranks.com

iBio Reports Fiscal Third Quarter 2025 Financial Results

May 2, 2025 | globenewswire.com

iBio, Inc.: iBio Raises $6.2 Million Through Warrant Inducement Transaction

April 30, 2025 | finanznachrichten.de

iBio, Inc. Announces Agreement to Exercise Existing Warrants for $6.2 Million in Gross Proceeds

April 29, 2025 | quiverquant.comQ

iBio Raises $6.2 Million Through Warrant Inducement Transaction

April 29, 2025 | globenewswire.com

iBio Enters Licensing Agreement for Obesity Treatment

April 22, 2025 | tipranks.com

iBio, Inc. Enters Licensing Agreement with AstralBio for First-in-Class Activin E-Targeting Antibody to Address Obesity and Cardiometabolic Diseases

April 22, 2025 | quiverquant.comQ

iBio Expands Cardiometabolic and Obesity Pipeline through Licensing of First-in-Class Antibody Targeting Activin E from AstralBio

April 22, 2025 | globenewswire.com

Ibio reports preclinical results for antibodies in cardiometabolic and obesity pipeline

April 8, 2025 | bioworld.comB

New MarketBeat Followers Over Time

Media Sentiment Over Time

IBIO, BRNS, FBLG, and ATHE Company Descriptions

Alterity Therapeutics NASDAQ:ATHE

$3.93 +0.01 (+0.26%)

Closing price 06/27/2025 03:57 PM Eastern

Extended Trading

$4.34 +0.41 (+10.43%)

As of 04:00 AM Eastern

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Barinthus Biotherapeutics NASDAQ:BRNS

$0.93 +0.01 (+0.81%)

Closing price 06/27/2025 03:58 PM Eastern

Extended Trading

$0.92 -0.01 (-1.51%)

As of 04:00 AM Eastern

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

FibroBiologics NASDAQ:FBLG

$0.62 -0.09 (-13.19%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.66 +0.04 (+6.94%)

As of 04:44 AM Eastern

FibroBiologics, Inc. operates as a cell therapy, regenerative medicine company. It is developing a pipeline of treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. It holds 150+ U.S. and internationally issued patents/patents pending across various clinical pathways, including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer. FibroBiologics, Inc. was incorporated in 2021 and is based in Houston, Texas.

iBio NYSE:IBIO

$0.76 +0.05 (+6.34%)

Closing price 06/27/2025 04:00 PM Eastern

Extended Trading

$0.73 -0.02 (-2.91%)

As of 05:09 AM Eastern

iBio, Inc., a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel. The company is also developing vaccine candidates, including IBIO-101, an antibody to reduce tumor growth; Endostatin E4 peptide for use in chemotherapy and immunotherapy; Trop-2 for the treatment Trop-2 positive cancers; MUC16, a tumor-associated epitope; anti-EGFRvIII antibody to treat glioblastoma and other cancers; CCR8 protein candidate for treatment of various cancers; PD-1 agonist for the treatment of rheumatoid arthritis and other inflammatory diseases; and IBIO-400 for the treatment of classical swine fever. iBio, Inc. has agreement with The Texas A&M University System for designing and manufacturing of plant-made biopharmaceuticals; and a research collaboration with the National Institute of Allergy and Infectious Diseases to investigate the potential of the company's AI-driven epitope steering platform for the development of a vaccine for Lassa fever. The company was incorporated in 2008 and is headquartered in Bryan, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time